share_log

Frontline Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga ·  Nov 27 15:11

Frontline plc (NYSE:FRO) will release earnings results for the third quarter, before the opening bell on Wednesday, Nov. 27.

Analysts expect Frontline to report quarterly earnings at 38 cents per share. That's up from 36 cents per share a year ago. The Limassol, Cyprus-based company projects to report quarterly revenue of $317.59 million, compared to $232.03 million a year earlier, according to data from Benzinga Pro.

On Aug. 30, Frontline reported better-than-expected second-quarter sales results.

Frontline shares fell 5% to close at $18.07 on Tuesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

  • Jefferies analyst Omar Nokta maintained a Buy rating and cut the price target from $30 to $26 on Nov. 14. This analyst has an accuracy rate of 70%.
  • BTIG analyst Gregory Lewis upgraded the stock from Neutral to Buy with a price target of $30 on Oct. 7. This analyst has an accuracy rate of 76%.
  • Evercore ISI Group analyst Jonathan Chappell maintained an Outperform rating and cut the price target from $33 to $32 on July 23. This analyst has an accuracy rate of 70%.
  • JP Morgan analyst Samuel Bland maintained a Neutral rating and cut the price target from $23 to $22.3 on March 1. This analyst has an accuracy rate of 72%.
  • Deutsche Bank analyst Amit Mehrotra upgraded the stock from Hold to Buy with a price target of $26 on Jan. 9. This analyst has an accuracy rate of 72%.

Considering buying FRO stock? Here's what analysts think:

big

Read This Next:

  • Jim Cramer: Linde Is A 'Terrific' Company, Sees Another Stock Up 75% As 'Not Done'
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment